JACC:冠脉功能异常的心绞痛和非阻塞性CAD患者预后较差

2019-11-16 国际循环编辑部 国际循环

约有50%接受心绞痛诊断性冠状动脉造影的患者无显著冠状动脉狭窄,但其中一部分可能存在冠状动脉功能异常。Akira Suda等研究者开展的一项研究全面评估心绞痛和非阻塞性冠心病(CAD)患者的冠状动脉功能异常对心外膜和微血管的重要性。

约有50%接受心绞痛诊断性冠状动脉造影的患者无显著冠状动脉狭窄,但其中一部分可能存在冠状动脉功能异常。Akira Suda等研究者开展的一项研究全面评估心绞痛和非阻塞性冠心病(CAD)患者的冠状动脉功能异常对心外膜和微血管的重要性。
 
研究前瞻性纳入187例患者(男性/女性113/74,63.2±12.3岁),他们接受乙酰胆碱激发试验以检测冠状动脉痉挛和微循环阻力指数(IMR),评估冠状动脉微血管功能。中位随访893天。
 


(图引自原文献)
 
结果显示,在所有受试者中,乙酰胆碱测试确定128例血管痉挛性心绞痛(VSA)患者(68%),随访期间10例患者发生心脏事件(5.3%)。多变量分析显示,IMR与心脏事件的发生率相关(HR=1.05;95%CI:1.02~1.09;P=0.002),并且受试者工作特征(ROC)曲线分析确定IMR为18.0是最佳选择。
 
根据IMR临界值和VSA的存在,在4组中,Kaplan-Meier生存分析显示,与其他组相比,IMR(≥18.0)和VSA高的组预后显著较其他组(log rank P=0.002)。重要的是,Rho激酶抑制剂法舒地尔的冠状动脉内给药可显著改善IMR升高的VSA患者的IMR(P<0.0001)。
 
研究表明,在患心绞痛和非阻塞性CAD的患者中,心外膜冠状动脉痉挛和微血管阻力增加并存时预后较差,这可能与Rho激酶激活有关。
 
原始出处:
Akira Suda, Jun Takahashi, Kiyotaka Hao, et al. Coronary Functional Abnormalities in Patients With Angina and Nonobstructive Coronary Artery Disease. JACC, November 2019.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1914375, encodeId=fdda19143e5fc, content=<a href='/topic/show?id=7c90328e6f1' target=_blank style='color:#2F92EE;'>#功能异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32876, encryptionId=7c90328e6f1, topicName=功能异常)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Jun 01 19:42:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696908, encodeId=e818169690865, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sun Oct 11 22:42:00 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692087, encodeId=e530169208e6d, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Aug 23 06:42:00 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854571, encodeId=c07918545e1dc, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Apr 12 00:42:00 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326397, encodeId=eb10132639eff, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Nov 18 13:42:00 CST 2019, time=2019-11-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1914375, encodeId=fdda19143e5fc, content=<a href='/topic/show?id=7c90328e6f1' target=_blank style='color:#2F92EE;'>#功能异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32876, encryptionId=7c90328e6f1, topicName=功能异常)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Jun 01 19:42:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696908, encodeId=e818169690865, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sun Oct 11 22:42:00 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692087, encodeId=e530169208e6d, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Aug 23 06:42:00 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854571, encodeId=c07918545e1dc, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Apr 12 00:42:00 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326397, encodeId=eb10132639eff, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Nov 18 13:42:00 CST 2019, time=2019-11-18, status=1, ipAttribution=)]
    2020-10-11 tomyang96
  3. [GetPortalCommentsPageByObjectIdResponse(id=1914375, encodeId=fdda19143e5fc, content=<a href='/topic/show?id=7c90328e6f1' target=_blank style='color:#2F92EE;'>#功能异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32876, encryptionId=7c90328e6f1, topicName=功能异常)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Jun 01 19:42:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696908, encodeId=e818169690865, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sun Oct 11 22:42:00 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692087, encodeId=e530169208e6d, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Aug 23 06:42:00 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854571, encodeId=c07918545e1dc, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Apr 12 00:42:00 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326397, encodeId=eb10132639eff, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Nov 18 13:42:00 CST 2019, time=2019-11-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1914375, encodeId=fdda19143e5fc, content=<a href='/topic/show?id=7c90328e6f1' target=_blank style='color:#2F92EE;'>#功能异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32876, encryptionId=7c90328e6f1, topicName=功能异常)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Jun 01 19:42:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696908, encodeId=e818169690865, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sun Oct 11 22:42:00 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692087, encodeId=e530169208e6d, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Aug 23 06:42:00 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854571, encodeId=c07918545e1dc, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Apr 12 00:42:00 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326397, encodeId=eb10132639eff, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Nov 18 13:42:00 CST 2019, time=2019-11-18, status=1, ipAttribution=)]
    2020-04-12 hbwxf
  5. [GetPortalCommentsPageByObjectIdResponse(id=1914375, encodeId=fdda19143e5fc, content=<a href='/topic/show?id=7c90328e6f1' target=_blank style='color:#2F92EE;'>#功能异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32876, encryptionId=7c90328e6f1, topicName=功能异常)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Jun 01 19:42:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696908, encodeId=e818169690865, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Sun Oct 11 22:42:00 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692087, encodeId=e530169208e6d, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Aug 23 06:42:00 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854571, encodeId=c07918545e1dc, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Apr 12 00:42:00 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326397, encodeId=eb10132639eff, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Nov 18 13:42:00 CST 2019, time=2019-11-18, status=1, ipAttribution=)]

相关资讯

黄伟光:急性胸痛的诊断和处理

急性胸痛约占急诊内科病人5%~20%,三级医院可能会达到20%~30%,急性胸痛的症状复杂多样,有些患者的胸痛发作急骤,病情迅速恶化,短时间内危及患者的生命。那么,急性胸痛如何诊断与处理呢?

JACC:稳定型心绞痛冠状动脉血运重建的预测

本研究旨在头对头比较冠状动脉CT血管造影(CTA)和心脏磁共振(CMR)应力灌注成像得出的血流储备分数(FFR)为血运重建标准,对行冠状动脉CTA检查的阻塞性冠状动脉疾病患者具有指导价值。FFRCT是一种新的无创功能检测方法。FFRCT与CMR应力灌注成像在有症状的冠状动脉疾病患者中的临床应用尚不清楚。研究纳入了已行冠状动脉CTA稳定型心绞痛患者(n=110),1处或1处以上冠状动脉狭窄≥50%,

Int J Cardiol:台湾营养与健康调查显示心绞痛患病率下降

由此可见,从1993-1996年期间到2005-2008年期间,AP的患病率显著下降。女性的AP患病率较高,男性患病率随年龄增长而增加,但女性则不然。建议持续监测AP患病率,以更好地了解该疾病的负担。

心绞痛有个“双胞胎”,症状一模一样心血管却粗黑光滑连医生都骗

这是一种连医生都骗的心血管问题。即使对于专业的心血管医生,也曾经发生过误判。

JAMA Intern Med:我国多中心随机研究:针灸可减轻稳定心绞痛患者症状

近期,JAMA内科学子刊上发表我国成都中医药大学的一项针灸的多中心随机研究。

European Heart Journal:介入治疗后心绞痛未缓解或复发怎么办?

在经皮冠状动脉介入治疗(PCI)后,20%~40%患者仍有心绞痛。 近期,欧洲心脏杂志发表文章,阐述了PCI术后心绞痛的潜在机制,并提出一种实用的诊疗流程。